Monoclonal antibody treatments that act on EGFR, including Cmab and Pmab, are recommended for Ras wild-type-metastatic colorectal cancer as candidates for first-line to third-line therapy [12–14]. Here, EGFR is linked to metastatic colorectal cancer.